Related references
Note: Only part of the references are listed.1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase
Mei-Jung Lai et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
SKLB060 Reversibly Binds to Colchicine Site of Tubulin and Possesses Efficacy in Multidrug-Resistant Cell Lines
Wei Yan et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site
Qinhuai Lai et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy
Souvik Banerjee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361)
Michael P. Smolinski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Synthesis and biological evaluation of 2-aryl- benzimidazole derivatives of dehydroabietic acid as novel tubulin polymerization inhibitors
Ting-Ting Miao et al.
RSC ADVANCES (2018)
Synthesis of thiazole linked indolyl-3-glyoxylamide derivatives as tubulin polymerization inhibitors
Sravanthi Devi Guggilapu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
A 4-Phenoxyphenol Derivative Exerts Inhibitory Effects on Human Hepatocellular Carcinoma Cells through Regulating Autophagy and Apoptosis Accompanied by Downregulating α-Tubulin Expression
Wen-Tsan Chang et al.
MOLECULES (2017)
Strategies and challenges for the next generation of antibody drug conjugates
Alain Beck et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Synthesis, in vitro and in vivo evaluation of new hybrids of millepachine and phenstatin as potent tubulin polymerization inhibitors
Baijiao An et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2017)
Anticancer activity of a novel small molecule tubulin inhibitor STK899704
Krisada Sakchaisri et al.
PLOS ONE (2017)
Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function
I. Kalhari Lindamulage et al.
SCIENTIFIC REPORTS (2017)
Triazole tethered isatin-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies
Harbinder Singh et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
Xiaoxin Wu et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2016)
Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents
Laxman Devkota et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Triazole tethered C5-curcuminoid-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies
Harbinder Singh et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Early investigational tubulin inhibitors as novel cancer therapeutics
Kunal Nepali et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Tubulin inhibitors in non-small cell lung cancer: looking back and forward
R. Ferrara et al.
EXPERT OPINION ON PHARMACOTHERAPY (2016)
Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Ya-Ting Ji et al.
CURRENT MEDICINAL CHEMISTRY (2015)
The Novel Tubulin Polymerization Inhibitor MHPT Exhibits Selective Anti-Tumor Activity against Rhabdomyosarcoma In Vitro and In Vivo
Yan Mu et al.
PLOS ONE (2015)
Design and Synthesis of Aminostilbene-Arylpropenones as Tubulin Polymerization Inhibitors
Ahmed Kamal et al.
CHEMMEDCHEM (2014)
Recent developments in tubulin polymerization inhibitors: An overview
Ramandeep Kaur et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Tubulin inhibitors: a patent review
Yi-Min Liu et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
Tubulin Inhibitors: A Patent Survey
Kunal Nepali et al.
Recent Patents on Anti-Cancer Drug Discovery (2014)
Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer
Parvin F. Peddi et al.
FUTURE ONCOLOGY (2013)
Development of a Novel Class of Tubulin Inhibitors with Promising Anticancer Activities
Jingle Xi et al.
MOLECULAR CANCER RESEARCH (2013)
Colchicine and its various physicochemical and biological aspects
Sameer Sapra et al.
MEDICINAL CHEMISTRY RESEARCH (2013)
MPTOB169, a New Tubulin Inhibitor, Inhibits Cell Growth and Induces G2/M Arrest in Nonresistant and Paclitaxel-Resistant Cancer Cells
Wei-Hwa Lee et al.
PHARMACOLOGY (2013)
Antibody Therapeutics in Cancer
Mark X. Sliwkowski et al.
SCIENCE (2013)
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
J. Cummings et al.
BRITISH JOURNAL OF CANCER (2012)
TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells
Daniel P. Fitzgerald et al.
MOLECULAR CANCER THERAPEUTICS (2012)
A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells
Ajita V. Singh et al.
BLOOD (2011)
Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
Laurent Ducry et al.
BIOCONJUGATE CHEMISTRY (2010)
Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors
Elizabeth Fox et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
Monica M. Mita et al.
CLINICAL CANCER RESEARCH (2010)
A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
P. D. Nathan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity
Howard W. Salmon et al.
CLINICAL CANCER RESEARCH (2006)
The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: Results of a phase 1 study
KR Hande et al.
CLINICAL CANCER RESEARCH (2006)
Combretastatin A4 phosphate: background and current clinical status
SL Young et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2004)
The biology of the combretastatins as tumour vascular targeting agents
GM Tozer et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2002)
Share Paper
